Seer
NASDAQ: SEERFounded 2017 · 3 known investors
Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples. Its products serve researchers running deep, reproducible proteomic studies at scale.
BiotechDeep TechHardwareHealthtech
Founders & leadership
Seer was founded in 2017 by Omid Farokhzad.
OF
Omid FarokhzadinChair and Chief Executive Officer
Investors · 3
Competitors · 1
by search overlapCompanies competing with Seer for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Seer do?
- Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples. Its products serve researchers running deep, reproducible proteomic studies at scale.
- Who founded Seer?
- Seer was founded by Omid Farokhzad in 2017.
- Who are Seer's investors?
- Seer's investors include SoftBank Vision Fund, Solasta Ventures, Maverick Ventures.